EPSTI1

Summary

EPSTI1 (epithelial stromal interaction 1, HGNC:16465) is a protein-coding gene on chromosome 13q14.11, encoding Epithelial-stromal interaction protein 1 (Q96J88). Plays a role in M1 macrophage polarization and is required for the proper regulation of gene expression during M1 versus M2 macrophage differentiation.

The protein encoded by this gene has been shown to promote tumor invasion and metastasis in some invasive cancer cells when overexpressed. Expression of this gene has been shown to be upregulated by direct binding of the Kruppel like factor 8 protein to promoter sequences. The translated protein interacts with the amino terminal region of the valosin containing protein gene product, resulting in the nuclear translocation of the nuclear factor kappa B subunit 1 gene product, and activation of target genes. Overexpression of this gene has been observed in some breast cancers and in some individuals with systemic lupus erythematosus (SLE).

Source: NCBI Gene 94240 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 96 total
• MANE Select transcript: NM_033255

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16465
Approved symbol	EPSTI1
Name	epithelial stromal interaction 1
Location	13q14.11
Locus type	gene with protein product
Status	Approved
Aliases	BRESI1, MGC29634
Ensembl gene	ENSG00000133106
Ensembl biotype	protein_coding
OMIM	607441
Entrez	94240

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 6 protein_coding, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000313624, ENST00000313640, ENST00000398762, ENST00000476830, ENST00000535677, ENST00000536042, ENST00000537828, ENST00000538562, ENST00000540470, ENST00000542706, ENST00000860858, ENST00000944922

RefSeq mRNA: 4 — MANE Select: NM_033255 NM_001002264, NM_001330543, NM_001331228, NM_033255

CCDS: CCDS31964, CCDS81765, CCDS9387

Canonical transcript exons

ENST00000313624 — 11 exons

Exon	Start	End
ENSE00002294298	42991978	42992241
ENSE00003483228	42953948	42954021
ENSE00003559599	42970612	42970670
ENSE00003580432	42895009	42895108
ENSE00003600406	42886388	42888502
ENSE00003611155	42963255	42963338
ENSE00003644086	42969094	42969177
ENSE00003646979	42964066	42964139
ENSE00003656763	42917541	42917624
ENSE00003662959	42926336	42926429
ENSE00003668230	42900310	42900383

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 99.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.3342 / max 1810.1230, expressed in 1407 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
137008	29.3342	1407

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	99.42	gold quality
secondary oocyte	CL:0000655	99.21	gold quality
ileal mucosa	UBERON:0000331	95.39	gold quality
monocyte	CL:0000576	94.77	gold quality
leukocyte	CL:0000738	94.63	gold quality
decidua	UBERON:0002450	92.78	gold quality
granulocyte	CL:0000094	92.39	gold quality
vermiform appendix	UBERON:0001154	92.30	gold quality
epithelial cell of pancreas	CL:0000083	91.39	gold quality
jejunal mucosa	UBERON:0000399	91.37	gold quality
palpebral conjunctiva	UBERON:0001812	91.14	gold quality
duodenum	UBERON:0002114	90.56	gold quality
amniotic fluid	UBERON:0000173	89.31	gold quality
epithelium of nasopharynx	UBERON:0001951	89.21	gold quality
nasopharynx	UBERON:0001728	89.20	gold quality
kidney epithelium	UBERON:0004819	88.86	silver quality
colonic epithelium	UBERON:0000397	88.79	gold quality
lymph node	UBERON:0000029	87.58	gold quality
pancreatic ductal cell	CL:0002079	87.28	gold quality
gall bladder	UBERON:0002110	86.71	gold quality
buccal mucosa cell	CL:0002336	86.59	silver quality
bone marrow cell	CL:0002092	86.55	gold quality
blood	UBERON:0000178	85.95	gold quality
nasal cavity epithelium	UBERON:0005384	85.60	silver quality
caecum	UBERON:0001153	85.50	gold quality
calcaneal tendon	UBERON:0003701	84.95	gold quality
germinal epithelium of ovary	UBERON:0001304	84.88	gold quality
bone marrow	UBERON:0002371	84.52	gold quality
tonsil	UBERON:0002372	84.29	gold quality
small intestine	UBERON:0002108	83.81	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-10662	yes	463.33
E-HCAD-6	yes	47.66
E-ANND-3	yes	7.13

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): KLF8

miRNA regulators (miRDB)

92 targeting EPSTI1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548N	99.98	71.94	4170
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509

Literature-anchored findings (GeneRIF, showing 12)

• These observations implicate EPSTI1 as a hitherto unappreciated regulator of tumor cell properties. (PMID:20133812)
• A novel KLF8 to EPSTI1 to VCP to NF-kappaB signaling mechanism potentially critical for breast cancer invasion and metastasis. (PMID:24096480)
• circEPSTI1,a significantly upregulated circRNA, which is derived from the EPSTI1 (epithelial stromal interaction 1) gene locus, is an independent prognostic marker for triple-negative breast cancer patient survival. (PMID:30083277)
• Data show that showed that circular RNAs (circEPSTI1) and EPSTI1 (epithelial stromal interaction 1) could directly bind to miR-942. (PMID:30887698)
• circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma. (PMID:31702512)
• Elevated EPSTI1 expression in primary Sjogren’s syndrome B cells promoted TLR9 signalling activation and contributed to the abnormal B cell activation, which was promoted by facilitating p65 phosphorylation and activation of NF-kappaB signalling via promoting IkappaBalpha degradation. (PMID:32114510)
• Role of epithelial - Stromal interaction protein-1 expression in breast cancer. (PMID:32769326)
• The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway. (PMID:32826876)
• Contrasting functions of the epithelialstromal interaction 1 gene, in human oral and lung squamous cell cancers. (PMID:34738627)
• Knockdown of EPSTI1 alleviates lipopolysaccharide-induced inflammatory injury through regulation of NF-kappaB signaling in a cellular pneumonia model. (PMID:35527663)
• EPSTI1 promotes monocyte adhesion to endothelial cells in vitro via upregulating VCAM-1 and ICAM-1 expression. (PMID:35778487)
• EPSTI1 as an immune biomarker predicts the prognosis of patients with stage III colon cancer. (PMID:36330510)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:194621	ENSDARG00000074696
danio_rerio	epsti1	ENSDARG00000094578
mus_musculus	Epsti1	ENSMUSG00000022014
rattus_norvegicus	Epsti1	ENSRNOG00000009471

Protein

Protein identifiers

Epithelial-stromal interaction protein 1 — Q96J88 (reviewed: Q96J88)

All UniProt accessions (3): Q96J88, F5H4H1, F5H799

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in M1 macrophage polarization and is required for the proper regulation of gene expression during M1 versus M2 macrophage differentiation. Might play a role in RELA/p65 and STAT1 phosphorylation and nuclear localization upon activation of macrophages.

Tissue specificity. Highly expressed in placenta, small intestine, spleen, kidney, thymus, liver, salivary gland and testes. Weakly expressed in breast, skeletal muscle and colon. Highly expressed in breast cancer upon interaction between tumor cells and stromal cells in vitro. Expressed in blood mononuclear cells from patients with systemic lupus erythematosus (SLE).

Induction. Up-regulated in breast carcinomas.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96J88-1	1	yes
Q96J88-2	2
Q96J88-3	3

RefSeq proteins (4): NP_001002264, NP_001317472, NP_001318157, NP_150280* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026185	EPSTI1	Family

UniProt features (9 total): coiled-coil region 2, splice variant 2, sequence variant 2, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96J88-F1	75.49	0.47

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9696273	RND1 GTPase cycle

MSigDB gene sets: 274 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, IRF7_01, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP, ACEVEDO_LIVER_CANCER_UP, ISRE_01, chr13q14, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP, YTAAYNGCT_UNKNOWN, CHEN_METABOLIC_SYNDROM_NETWORK, HORIUCHI_WTAP_TARGETS_UP, BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE, CSR_LATE_UP.V1_DN, REACTOME_RHO_GTPASE_CYCLE, GSE14415_FOXP3_KO_NATURAL_TREG_VS_TCONV_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

1042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EPSTI1	IFI44L	Q53G44	646
EPSTI1	HERC5	Q9UII4	620
EPSTI1	CMPK2	Q5EBM0	614
EPSTI1	LY6E	Q16553	592
EPSTI1	IFIT5	Q13325	588
EPSTI1	IFI44	Q8TCB0	581
EPSTI1	USP18	Q9UMW8	575
EPSTI1	OASL	Q15646	564
EPSTI1	IFIT3	O14879	559
EPSTI1	IFI6	P09912	553
EPSTI1	MX1	P20591	541
EPSTI1	PARP9	Q8IXQ6	531
EPSTI1	RSAD2	Q8WXG1	522
EPSTI1	SAMD9L	Q8IVG5	520
EPSTI1	OAS3	Q9Y6K5	507

IntAct

18 interactions, top by confidence:

A	B	Type	Score
EPSTI1	DDX21	psi-mi:“MI:0915”(physical association)	0.400
AKT1	EPSTI1	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	AURKA	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	BAG4	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	BCAR3	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	CASP8	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	CDH1	psi-mi:“MI:0915”(physical association)	0.370
ESR1	EPSTI1	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	FGFR4	psi-mi:“MI:0915”(physical association)	0.370
NOTCH2	EPSTI1	psi-mi:“MI:0915”(physical association)	0.370
EPSTI1	PPM1D	psi-mi:“MI:0915”(physical association)	0.370
PTPRJ	EPSTI1	psi-mi:“MI:0915”(physical association)	0.370
RB1CC1	EPSTI1	psi-mi:“MI:0915”(physical association)	0.370
CUL1	LGALS8	psi-mi:“MI:0914”(association)	0.350
EPSTI1	CST4	psi-mi:“MI:0914”(association)	0.350
EPSTI1	MVK	psi-mi:“MI:0914”(association)	0.350
	EPSTI1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (31): EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), EPSTI1 (Two-hybrid), SERPINA5 (Affinity Capture-MS), SNTG2 (Affinity Capture-MS), CST2 (Affinity Capture-MS)

ESM2 similar proteins: A0MZ67, A1L1K1, A2AVJ5, A5A6J4, B0BM24, M0R3K6, O95990, Q0P4B9, Q28IH8, Q2KI00, Q2KI52, Q2MJV9, Q2NL11, Q32PN7, Q3B820, Q3MHH7, Q3TGF2, Q4KM62, Q4R2Y2, Q4V7W3, Q4V817, Q561Q8, Q561X3, Q5BK43, Q5E9R0, Q5NVP3, Q5RG44, Q5U4F3, Q5XG48, Q62736, Q66KE9, Q6AY14, Q6AYN9, Q6P3G4, Q78TU8, Q7T0S7, Q8CB59, Q8CJ96, Q8K2Q9, Q96J88

Diamond homologs: Q5BK43, Q8VDI1, Q96J88

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	70
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2184 predictions. Top by Δscore:

Variant	Effect	Δscore
13:42900308:ACCT:A	donor_gain	1.0000
13:42900309:CCTC:C	donor_gain	1.0000
13:42900311:T:TA	donor_gain	1.0000
13:42926434:C:CT	acceptor_gain	1.0000
13:42926435:A:T	acceptor_gain	1.0000
13:42953946:A:AC	donor_gain	1.0000
13:42953947:C:CC	donor_gain	1.0000
13:42953947:CT:C	donor_gain	1.0000
13:42953947:CTA:C	donor_gain	1.0000
13:42954028:T:TC	acceptor_gain	1.0000
13:42963249:CCTTA:C	donor_loss	1.0000
13:42963250:CTTAC:C	donor_loss	1.0000
13:42963251:TTACC:T	donor_loss	1.0000
13:42963252:TACCT:T	donor_loss	1.0000
13:42963253:A:C	donor_loss	1.0000
13:42963254:C:G	donor_loss	1.0000
13:42963344:T:C	acceptor_gain	1.0000
13:42963344:T:TC	acceptor_gain	1.0000
13:42963349:T:TC	acceptor_gain	1.0000
13:42963355:T:TC	acceptor_gain	1.0000
13:42969089:CTTA:C	donor_loss	1.0000
13:42969090:TTAC:T	donor_loss	1.0000
13:42969091:TA:T	donor_loss	1.0000
13:42969093:CCTAG:C	donor_gain	1.0000
13:42969175:CAA:C	acceptor_gain	1.0000
13:42969178:C:CC	acceptor_gain	1.0000
13:42969184:C:CT	acceptor_gain	1.0000
13:42969184:C:T	acceptor_gain	1.0000
13:42969185:A:T	acceptor_gain	1.0000
13:42969188:C:CT	acceptor_gain	1.0000

AlphaMissense

2023 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:42895093:A:C	F288L	0.981
13:42895093:A:T	F288L	0.981
13:42895095:A:G	F288L	0.981
13:42969175:C:G	A84P	0.969
13:42964111:T:A	R120S	0.957
13:42964111:T:G	R120S	0.957
13:42895094:A:G	F288S	0.948
13:42969153:A:G	L91P	0.948
13:42970628:T:A	R77S	0.948
13:42970628:T:G	R77S	0.948
13:42964103:T:G	Q123P	0.931
13:42895094:A:C	F288C	0.926
13:42963273:C:A	K157N	0.925
13:42963273:C:G	K157N	0.925
13:42969162:A:G	L88P	0.925
13:42970632:C:G	R76P	0.925
13:42895091:A:G	L289P	0.918
13:42964083:A:G	S130P	0.913
13:42964091:A:G	L127P	0.910
13:42969174:G:T	A84E	0.910
13:42963261:T:A	R161S	0.907
13:42963261:T:G	R161S	0.907
13:42895085:C:G	R291P	0.903
13:42969145:A:G	W94R	0.903
13:42969145:A:T	W94R	0.903
13:42969140:C:A	K95N	0.901
13:42969140:C:G	K95N	0.901
13:42963293:C:G	A151P	0.900
13:42963302:C:G	A148P	0.900
13:42969143:C:A	W94C	0.900

dbSNP variants (sampled 300 via entrez): RS1000016425 (13:42929308 T>C,G), RS1000037264 (13:42954835 G>A,C), RS1000040097 (13:42939991 C>T), RS1000047337 (13:42968048 G>T), RS1000069547 (13:42936233 C>G), RS1000073632 (13:42982128 T>C), RS1000096752 (13:42979048 G>A,T), RS1000116889 (13:42892247 C>T), RS1000138881 (13:42980493 G>A), RS1000148323 (13:42933564 C>G), RS1000196283 (13:42965058 C>T), RS1000210447 (13:42904720 CA>C), RS1000212743 (13:42916780 A>C), RS1000223606 (13:42957164 G>A,C), RS1000229557 (13:42947329 C>T)

Disease associations

OMIM: gene MIM:607441 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001762_498	Obesity-related traits	7.000000e-07
GCST005758_4	Dimensional psychopathology (Arousal)	1.000000e-06
GCST006304_12	Irritable bowel syndrome	3.000000e-06
GCST006979_1103	Heel bone mineral density	4.000000e-12
GCST008358_2	Response to cognitive-behavioural therapy in anxiety and major depressive disorders	5.000000e-06
GCST009442_4	Age-related cognitive decline (executive function) (slope of z-scores)	4.000000e-06
GCST009734_8	Severe aplastic anemia	8.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004344	birth weight
EFO:0009099	arousal domain measurement
EFO:0009270	heel bone mineral density
EFO:0007820	cognitive behavioural therapy
EFO:0007710	cognitive decline measurement
EFO:0006927	severe aplastic anemia

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	7
trichostatin A	increases expression, affects cotreatment	3
bisphenol A	increases methylation, decreases expression	2
potassium chromate(VI)	decreases expression, affects cotreatment	2
mercuric bromide	increases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
Panobinostat	affects cotreatment, increases expression	2
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
methylmercuric chloride	decreases expression	1
sodium arsenite	affects expression	1
S-(1,2-dichlorovinyl)cysteine	decreases reaction, increases expression	1
M-VAC protocol	decreases response to substance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
dinophysistoxin 1	decreases expression	1
chromium hexavalent ion	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic Trioxide	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Calcitriol	decreases expression	1
Carbamazepine	affects expression	1
Chenodeoxycholic Acid	affects cotreatment, increases expression	1
Demecolcine	increases expression	1

Cellosaurus cell lines

5 cell lines: 5 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1F8	Abcam A-549 EPSTI1 KO 2	Cancer cell line	Male
CVCL_B2MR	Abcam A-549 EPSTI1 KO 1	Cancer cell line	Male
CVCL_E1W6	HAP1 EPSTI1 (-) 2	Cancer cell line	Male
CVCL_E1W7	HAP1 EPSTI1 (-) 3	Cancer cell line	Male
CVCL_XN49	HAP1 EPSTI1 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer